Latest issue out now. Keep up to date on the most recent regulatory changes in the world of pharma, biotech and medical device clinical trials with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribe...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Preparing For The Biosimilar Era Of ADCs And BsAbs In Oncology
In a recent interview with Citeline, the head of ICON's Centre for Biosimilar Drug Development discussed the upcoming patent expirations in oncology biologics, the opportunities, regulatory pathways and challenges this presents for developers and greater treatment access for patients.
-
What sets oncology biosimilars apart: Anticipating key challenges in the development landscape
Advancements in biologic therapies have greatly improved our ability to treat cancer over the last few decades — but are typically very costly. With patent expirations encompassing numerous notable oncology biologics, opportunities for oncology biosimilar development are abundant.
-
The Evolving Cost-Benefit Landscape of Biosimilar Drug Development
The patent cliff for biologic medicines presents an opportunity for developers of biosimilars, but historically there are challenges too. The landscape however is changing, supporting easier paths to market.
-
The U.S. biosimilars market: Shaking the “laggard” label
An article by Katya Svoboda and Bob Swann which explores the fundamental differences in the regulatory processes and the market dynamics of the US and the EU which account for much of the discrepancy in the uptake of biosimilars.
